{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T12:57:13Z","timestamp":1786366633249,"version":"build-2736575974"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["1Q4DBKX4STIP320"],"award-info":[{"award-number":["1Q4DBKX4STIP320"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","award":["FK128582"],"award-info":[{"award-number":["FK128582"]}],"id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.thromres.2023.01.010","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T02:02:46Z","timestamp":1674439366000},"page":"44-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Patients with multiple myeloma and monoclonal gammopathy of undetermined significance have variably increased thrombin generation and different sensitivity to the anticoagulant effect of activated protein C"],"prefix":"10.1016","volume":"223","author":[{"given":"Harriet","family":"Ghansah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3 Beke","family":"Debreceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"V\u00e1r\u00f3czy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e1szl\u00f3","family":"Rejt\u0151","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"L\u00f3czi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsuzsa","family":"Bagoly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e1nos","family":"Kappelmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2023.01.010_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2012\/783214","article-title":"Venous thromboembolism in cancer patients undergoing major abdominal surgery: prevention and management","volume":"2012","author":"Rao","year":"2012","journal-title":"ISRN Vasc. Med."},{"issue":"4","key":"10.1016\/j.thromres.2023.01.010_bb0010","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/s-0037-1613051","article-title":"Venous thrombosis in patients with solid tumors: determination of frequency and characteristics","volume":"87","author":"Sallah","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2023.01.010_bb0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1634\/theoncologist.2016-0214","article-title":"Cancer and venous thromboembolic disease: a review","volume":"22","author":"Donnellan","year":"2017","journal-title":"Oncologist"},{"issue":"SUPPL. 23","key":"10.1016\/j.thromres.2023.01.010_bb0020","article-title":"Venous thromboembolism and cancer: risks and outcomes","volume":"107","author":"Lee","year":"2003","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.thromres.2023.01.010_bb0025","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.ejca.2012.10.021","article-title":"Incidence of venous thromboembolism in patients with cancer-a cohort study using linked United Kingdom databases","volume":"49","author":"Walker","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"9","key":"10.1016\/j.thromres.2023.01.010_bb0030","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1182\/blood-2008-04-151076","article-title":"Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"112","author":"Kristinsson","year":"2008","journal-title":"Blood"},{"issue":"SUPPL. 1","key":"10.1016\/j.thromres.2023.01.010_bb0035","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1016\/S0049-3848(12)70024-5","article-title":"PL-17 risk and management of thrombosis in multiple myeloma","volume":"129","author":"Leebeek","year":"2012","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.thromres.2023.01.010_bb0040","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1586\/14737140.7.3.307","article-title":"Thrombosis in multiple myeloma","volume":"7","author":"Zangari","year":"2007","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"SUPPL. 2","key":"10.1016\/j.thromres.2023.01.010_bb0045","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0305-7372(10)70009-8","article-title":"Management of treatment-related adverse events in patients with multiple myeloma","volume":"36","author":"Mateos","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.thromres.2023.01.010_bb0050","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2009-12-257519","article-title":"High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study","volume":"116","author":"Libourel","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.thromres.2023.01.010_bb0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1055\/s-0031-1273085","article-title":"Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis","volume":"37","author":"Zamagni","year":"2011","journal-title":"Semin. Thromb. Hemost."},{"issue":"2","key":"10.1016\/j.thromres.2023.01.010_bb0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.clml.2011.03.006","article-title":"Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide\/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens","volume":"11","author":"Zangari","year":"2011","journal-title":"Clin. Lymphoma, Myeloma Leuk."},{"issue":"16","key":"10.1016\/j.thromres.2023.01.010_bb0065","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.3390\/ijms22168955","article-title":"The proteasome inhibitor bortezomib induces apoptosis and activation in gel-filtered human platelets","volume":"22","author":"Ghansah","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.thromres.2023.01.010_bb0070","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3324\/haematol.2012.064444","article-title":"Thrombosis is associated with inferior survival in multiple myeloma","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.thromres.2023.01.010_bb0075","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.thromres.2023.01.010_bb0080","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.thromres.2023.01.010_bb0085","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.thromres.2023.01.010_bb0090","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma epidemiology and survival: a unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Semin. Oncol."},{"issue":"12","key":"10.1016\/j.thromres.2023.01.010_bb0095","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.thromres.2023.01.010_bb0100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0609.2010.01539.x","article-title":"Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism","volume":"86","author":"Gregersen","year":"2011","journal-title":"Eur. J. Haematol."},{"issue":"11","key":"10.1016\/j.thromres.2023.01.010_bb0105","doi-asserted-by":"crossref","first-page":"5340","DOI":"10.1182\/blood.V112.11.5340.5340","article-title":"Venous thromboembolism (VTE) in patients (pts.) with monoclonal gammopathy of undetermined significance (MGUS)","volume":"112","author":"Muslimani","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.thromres.2023.01.010_bb0110","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/annonc\/mdh385","article-title":"The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance","volume":"15","author":"Sallah","year":"2004","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.thromres.2023.01.010_bb0115","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/cncr.20405","article-title":"Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease","volume":"101","author":"Srkalovic","year":"2004","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.thromres.2023.01.010_bb0120","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin. Proc."},{"issue":"3","key":"10.1016\/j.thromres.2023.01.010_bb0125","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.thromres.2009.01.004","article-title":"The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease","volume":"125","author":"Cohen","year":"2010","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.thromres.2023.01.010_bb0130","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/bjh.12168","article-title":"Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients","volume":"160","author":"Za","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2023.01.010_bb0135","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2141.2001.03061.x","article-title":"Interleukin 6 and haemostasis","volume":"115","author":"Kerr","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.thromres.2023.01.010_bb0140","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1016\/j.ejca.2010.03.007","article-title":"Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis","volume":"46","author":"Uaprasert","year":"2010","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.thromres.2023.01.010_bb0145","first-page":"33","article-title":"Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma","volume":"266","author":"Carr","year":"1994","journal-title":"Am. J. Physiol. Hear. Circ. Physiol."},{"issue":"1","key":"10.1016\/j.thromres.2023.01.010_bb0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-2143(96)90116-X","article-title":"Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma","volume":"128","author":"Carr","year":"1996","journal-title":"J. Lab. Clin. Med."},{"key":"10.1016\/j.thromres.2023.01.010_bb0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/(SICI)1096-8652(199910)62:2<99::AID-AJH6>3.0.CO;2-N","article-title":"Light-chain paraproteins with lupus anticoagulant activity","volume":"62","author":"Yasin","year":"1999","journal-title":"Am. J. Hematol."},{"issue":"4","key":"10.1016\/j.thromres.2023.01.010_bb0160","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2006.06208.x","article-title":"Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism","volume":"134","author":"Elice","year":"2006","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.thromres.2023.01.010_bb0165","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/eci.12269","article-title":"Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma","volume":"44","author":"Undas","year":"2014","journal-title":"Eur. J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.thromres.2023.01.010_bb0170","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3324\/haematol.10454","article-title":"Prothrombotic coagulation abnormalities in patients with newly diagnosed multiple myeloma","volume":"92","author":"Auwerda","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2023.01.010_bb0175","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/asheducation-2007.1.158","article-title":"Bleeding and thrombosis risks in plasma cell dyscrasias","author":"Eby","year":"2007","journal-title":"Hematol. Am. Soc. Hematol. Educ. Progr."},{"issue":"3","key":"10.1016\/j.thromres.2023.01.010_bb0180","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1538-7836.2003.00083.x","article-title":"Extremely high levels of von willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment","volume":"1","author":"Minnema","year":"2003","journal-title":"J. Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2023.01.010_bb0185","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.leukres.2007.12.002","article-title":"Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens","volume":"32","author":"van Marion","year":"2008","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.thromres.2023.01.010_bb0190","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.seminhematol.2010.11.002","article-title":"Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance","volume":"48","author":"Kristinsson","year":"2011","journal-title":"Semin. Hematol."},{"issue":"12","key":"10.1016\/j.thromres.2023.01.010_bb0195","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.3109\/10428194.2015.1041385","article-title":"Thromboelastography, thrombin generation test and thrombodynamics reveal hypercoagulability in patients with multiple myeloma","volume":"56","author":"Gracheva","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.thromres.2023.01.010_bb0200","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/ijlh.13093","article-title":"The hypercoagulable state in multiple myeloma: the contribution of thrombin generation test","volume":"41","author":"Baccouche","year":"2019","journal-title":"Int. J. Lab. Hematol."},{"issue":"10","key":"10.1016\/j.thromres.2023.01.010_bb0205","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1538-7836.2008.03117.x","article-title":"High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study","volume":"6","author":"Besser","year":"2008","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2023.01.010_bb0210","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2141.2007.06738.x","article-title":"Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence","volume":"138","author":"Van Hylckama Vlieg","year":"2007","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.thromres.2023.01.010_bb0215","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1538-7836.2008.03018.x","article-title":"High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism","volume":"6","author":"Tripodi","year":"2008","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.thromres.2023.01.010_bb0220","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1076029615625825","article-title":"Plasma thrombin generation and sensitivity to activated protein C among patients with myeloma and monoclonal gammopathy of undetermined significance","volume":"22","author":"Crowley","year":"2016","journal-title":"Clin. Appl. Thromb."},{"issue":"4","key":"10.1016\/j.thromres.2023.01.010_bb0225","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/10428194.2016.1219900","article-title":"Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma","volume":"58","author":"Tiong","year":"2017","journal-title":"Leuk. Lymphoma"},{"issue":"November 2020","key":"10.1016\/j.thromres.2023.01.010_bb0230","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.thromres.2021.03.015","article-title":"Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"202","author":"Nielsen","year":"2021","journal-title":"Thromb. Res."},{"issue":"March","key":"10.1016\/j.thromres.2023.01.010_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcmd.2017.03.010","article-title":"Thrombin generation as a predictor of thromboembolic events in multiple myeloma patients","volume":"65","author":"Leiba","year":"2017","journal-title":"Blood Cells Mol. Dis."},{"issue":"1","key":"10.1016\/j.thromres.2023.01.010_bb0240","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/rth2.12161","article-title":"Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: an observational cohort study","volume":"3","author":"Chalayer","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.thromres.2023.01.010_bb0245","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1538-7836.2005.01168.x","article-title":"Mechanisms for acquired activated protein C resistance in cancer patients [1]","volume":"3","author":"Sarig","year":"2005","journal-title":"J. Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.thromres.2023.01.010_bb0250","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0002-9343(00)00691-4","article-title":"Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism","volume":"110","author":"Haim","year":"2001","journal-title":"Am. J. Med."},{"issue":"15","key":"10.1016\/j.thromres.2023.01.010_bb0255","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.thromres.2023.01.010_bb0260","doi-asserted-by":"crossref","first-page":"pp","DOI":"10.1038\/s41408-018-0135-y","article-title":"Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results","volume":"8","author":"Fotiou","year":"2018","journal-title":"Blood Cancer J."},{"issue":"August","key":"10.1016\/j.thromres.2023.01.010_bb0265","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2017.08.011","article-title":"Hypocoagulability as assessed by thrombin generation test in newly-diagnosed patients with multiple myeloma","volume":"66","author":"Legendre","year":"2017","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.thromres.2023.01.010_bb0270","first-page":"1","article-title":"Acquired activated protein C resistance and thrombosis in multiple myeloma patients","volume":"vol. 4, no. Mm","author":"Jim\u00e9nez-Zepeda","year":"2006","journal-title":"Thromb. J."},{"issue":"1","key":"10.1016\/j.thromres.2023.01.010_bb0275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-0037-1613747","article-title":"High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism","volume":"83","author":"Kraaijenhagen","year":"2000","journal-title":"Thromb. Haemost."},{"issue":"7","key":"10.1016\/j.thromres.2023.01.010_bb0280","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1056\/NEJM200008173430702","article-title":"High plasma levels of factor VIII and the risk of recurrent venous thromboembolism","volume":"343","author":"Kyrle","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.thromres.2023.01.010_bb0285","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1046\/j.1365-2141.2001.03089.x","article-title":"High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von willebrand factor and factor VIII gene","volume":"115","author":"Kamphuisen","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2023.01.010_bb0290","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12288-019-01092-y","article-title":"Elevated Von willebrand factor antigen levels are an independent risk factor for venous thromboembolism: first report from North India","volume":"35","author":"Rajpal","year":"2019","journal-title":"Indian J. Hematol. Blood Transfus."},{"issue":"7","key":"10.1016\/j.thromres.2023.01.010_bb0295","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3816\/CLM.2007.n.027","article-title":"Prothrombotic coagulation abnormalities in patients with paraprotein-producing B-cell disorders","volume":"7","author":"Auwerda","year":"2007","journal-title":"Clin. Lymphoma Myeloma"},{"issue":"2","key":"10.1016\/j.thromres.2023.01.010_bb0300","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.leu.2404067","article-title":"Bone marrow angiogenesis in multiple myeloma","volume":"20","author":"Vacca","year":"2006","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.thromres.2023.01.010_bb0305","first-page":"2210","article-title":"Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis","volume":"8","author":"Rajkumar","year":"2002","journal-title":"Clin. Cancer Res."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:49:56Z","timestamp":1758736196000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384823000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":61,"alternative-id":["S0049384823000105"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2023.01.010","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patients with multiple myeloma and monoclonal gammopathy of undetermined significance have variably increased thrombin generation and different sensitivity to the anticoagulant effect of activated protein C","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2023.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}